Home Cart Sign in  
Chemical Structure| 61-68-7 Chemical Structure| 61-68-7

Structure of Mefenamic Acid
CAS No.: 61-68-7

Chemical Structure| 61-68-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mefenamic Acid is an inhibitor of COX2 with anti-inflammatory properties, it's a non-steroidal anti-inflammatory agent.

Synonyms: C.I. 473; CN-35355; Apo Mefenamic

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Wegner, Scott A ; Kim, Hahn ; Avalos, José L ;

Abstract: Lactate transport plays a crucial role in the metabolism, microenvironment, and survival of cancer cells. However, current drugs targeting either MCT1 or MCT4, which traditionally mediate lactate import or efflux respectively, show limited efficacy beyond in vitro models. This limitation partly arises from the existence of both isoforms in certain tumors, however existing high-affinity MCT1/4 inhibitors are years away from human testing. Therefore, we conducted an optogenetic drug screen in Saccharomyces cerevisiae on a subset of the FDA-approved drug library to identify existing scaffolds that could be repurposed as monocarboxylate transporter (MCT) inhibitors. Our findings show that several existing drug classes inhibit MCT1 activity, including non-steroidal estrogens, non-steroidal anti-inflammatory drugs (NSAIDs), and natural products (in total representing approximately 1% of the total library, 78 out of 6400), with a moderate affinity (IC50 1.8–21 μM). Given the well-tolerated nature of NSAIDs, and their known anticancer properties associated with COX inhibition, we chose to further investigate their MCT1 inhibition profile. The majority of NSAIDs in our screen cluster into a single large structural grouping. Moreover, this group is predominantly comprised of FDA-approved NSAIDs, with seven exhibiting moderate MCT1 inhibition. Since these molecules form a distinct structural cluster with known NSAID MCT4 inhibitors, such as diclofenac, ketoprofen, and indomethacin, we hypothesize that these newly identified inhibitors may also inhibit both transporters. Consequently, NSAIDs as a class, and piroxicam specifically (IC50 4.4 μM), demonstrate MCT1 inhibition at theoretically relevant human dosages, suggesting immediate potential for standalone MCT inhibition or combined anticancer therapy.

Purchased from AmBeed: ; ; ; ; ; ; ; ;

Alternative Products

Product Details of Mefenamic Acid

CAS No. :61-68-7
Formula : C15H15NO2
M.W : 241.29
SMILES Code : C1=C(C(=CC=C1)C(O)=O)NC2=C(C(=CC=C2)C)C
Synonyms :
C.I. 473; CN-35355; Apo Mefenamic
MDL No. :MFCD00051721
InChI Key :HYYBABOKPJLUIN-UHFFFAOYSA-N
Pubchem ID :4044

Safety of Mefenamic Acid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • COX-1

In Vitro:

Cell Line
Concentration Treated Time Description References
Pig urethral smooth muscle cells 300 µM 5 min To investigate the effects of mefenamic acid on voltage-dependent Ba2+ inward currents, the results showed that mefenamic acid increased voltage-dependent Ba2+ inward currents through the activation of L-type Ca2+ channels. Br J Pharmacol. 2005 Apr;144(7):919-25.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse Air pouch inflammation model Intraperitoneal injection 50 mg/kg Single dose Inhibited NLRP3 inflammasome-dependent IL-1β release Nat Commun. 2016 Aug 11;7:12504

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02580344 Contraception Phase 2 Completed - Egypt ... More >> Assiut university Assiut, Egypt, 71111 Less <<
NCT02968823 Pain, Postoperative ... More >> Surgery, Oral Less << Not Applicable Recruiting December 2019 Austria ... More >> MUVienna Recruiting Vienna, Austria Contact: Olga Plattner       olga.plattner@meduniwien.ac.at Less <<
NCT02943655 Improve Quality of Life ... More >> Heavy Menstrual Bleeding Less << Phase 3 Recruiting February 2019 Egypt ... More >> Ahmed Abbas Recruiting Assiut, Cairo, Egypt, 002 Contact: ahmed abbas       bmr90@hotmail.com Less <<
NCT03383133 Metabolic Side Effects of Drug... More >>s Less << Early Phase 1 Not yet recruiting April 2018 -
NCT02417337 Pain Postoper... More >>ative Pain Irreversible Pulpitis Less << Phase 2 Completed - Sudan ... More >> University of Khartoum, Faculty of Dentistry, Khartoum, Sudan, 111-11 Less <<
NCT01598012 Primary Dysmenorrhea Phase 4 Completed - Thailand ... More >> Gynecologic Endocrinology Unit, Department of Obstetric and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok, Thailand, 10700 Less <<
NCT01942122 Endometrioma ... More >>Visual Analogue Pain Scale: Moderate or Severe Pain Less << Phase 2 Phase 3 Recruiting February 2019 Indonesia ... More >> Yasmin Clinic, Dr. Cipto Mangunkusumo Hospital (Kencana) Recruiting Jakarta Pusat, Jakarta, Indonesia, 10430 Contact: Kanadi Sumapraja, SpOG(K), MD    +6221 3928720    kanadisuma@yahoo.com    Contact: Budi Wiweko, SpOG(K), MD    +6221 39831098    wiwekobudi@yahoo.co.id    Sub-Investigator: R. Muharam, SpOG(K), MD          Sub-Investigator: Andon Hestiantoro, SpOG(K), MD          Sub-Investigator: Budi Wiweko, SpOG(K), MD          Sub-Investigator: Herbert Situmorang, SpOG(K), MD          Sub-Investigator: Gita Pratama, SpOG(K), MD          Sub-Investigator: Achmad K Harzif, SpOG, MD          Sub-Investigator: Mila Maidarti, SpOG, MD          Sub-Investigator: Vita Silvana, SpOG, MD          Department of Obstetrics and Gynecology, RSUP Persahabatan Recruiting Jakarta Pusat, Jakarta, Indonesia Contact: Botefilia, SpOG (K), MD    +62214891708    botefilia@yahoo.com    Principal Investigator: Botefilia, SpOG (K), MD          Sub-Investigator: Zakia, SpOG, MD          Sub-Investigator: Devi Marischa, SpOG, MD          Department of Obstetrics and Gynecology RSUP Fatmawati Recruiting Jakarta, Indonesia Contact: Agus S As'adi, SpOG (K), MD    +62217501524    agus_surur_asadi@yahoo.com    Principal Investigator: Agus S As'adi, SpOG (K), MD          Sub-Investigator: Luky S Syahbana, SpOG (K), MD          Sub-Investigator: Malvin, SpOG (K), MD Less <<
NCT01295294 Uterine Hemorrhage Phase 4 Completed - Denmark ... More >> København NV, Denmark, DK-2400 Odense C, Denmark, DK-5000 Skive, Denmark, DK-7800 Søborg, Denmark, DK-2860 Ålborg, Denmark, DK-9000 Århus C, Denmark, DK-8000 Ireland Mallow, Cork, Ireland Blackrock, Dublin, Ireland Cork, Ireland Norway Elverum, Norway, 2403 Haugesund, Norway, 5507 Trondheim, Norway, 7012 Less <<
NCT02183025 Dysmenorrhea Phase 2 Completed - -
NCT03070678 Diabetes Mellitus Phase 1 Completed - France ... More >> Investigational site 250001 Gières, France Less <<
NCT03323671 Primary Dysmenorrhea Phase 2 Phase 3 Completed - Egypt ... More >> Mansoura University Mansourah, Egypt, 35516 Less <<
NCT01060696 Infertility Not Applicable Unknown May 2010 Thailand ... More >> Siriraj hospital Mahidol university Bangkok, Thailand, 10700 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.14mL

0.83mL

0.41mL

20.72mL

4.14mL

2.07mL

41.44mL

8.29mL

4.14mL

References

 

Historical Records

Categories